In a patient with elevated eosinophils, toxic granulation, echinocytes, and anisocytosis, what is the appropriate diagnostic work‑up and management?

Diagnostic Work-Up and Management of Elevated Eosinophils with Toxic Granulation, Echinocytes, and Anisocytosis

In a patient with elevated eosinophils alongside toxic granulation, echinocytes, and anisocytosis, immediately obtain a detailed travel and exposure history, calculate the absolute eosinophil count (AEC), and initiate a structured diagnostic algorithm prioritizing helminth infections and secondary causes before considering primary eosinophilic disorders.

Initial Assessment and Risk Stratification

The presence of toxic granulation, echinocytes, and anisocytosis suggests concurrent systemic illness or infection beyond simple eosinophilia. Your first step is calculating the AEC (percentage of eosinophils × total WBC count):

• Eosinophilia: AEC >500 cells/μL
• Hypereosinophilia: AEC ≥1,500 cells/μL 1

This distinction is critical—hypereosinophilia rarely results from allergy alone and mandates comprehensive investigation 1.

Critical History Elements

Travel and Exposure History

Obtain specific details about:

• Geographic locations visited (particularly sub-Saharan Africa, Southeast Asia, South America)
• Freshwater exposure (lakes, rivers, swimming) within the past 2-8 weeks
• Timing of symptom onset relative to travel
• Raw or undercooked food consumption (freshwater crab, crayfish, wild boar)
• Walking barefoot in endemic regions 2

Medication History

Document all medications started within 3 months of eosinophilia onset, as drug-induced eosinophilia commonly presents with pulmonary involvement 2.

Symptom Assessment for End-Organ Damage

Specifically inquire about:

• Respiratory: fever, cough, wheeze, hemoptysis, dyspnea
• Gastrointestinal: abdominal pain, diarrhea, dysentery, weight loss
• Dermatologic: urticaria, rash, pruritus
• Cardiac: chest pain, palpitations (eosinophil-mediated myocarditis risk)
• Neurologic: headache, focal deficits (CNS involvement) 2

Diagnostic Algorithm

First-Line Investigations

For ALL patients with eosinophilia:

1. Stool studies (3 separate samples):

   • Concentrated stool microscopy
   • Stool PCR for helminths
   • Strongyloides serology (critical—stool microscopy has lower sensitivity) 2

2. Schistosomiasis serology (if any freshwater exposure in endemic areas within past 2-8 weeks) 2

3. HIV testing per BHIVA guidelines (HIV associated with eosinophilia, though helminth co-infection more likely) 2

4. Chest radiograph (assess for infiltrates, nodules, cavitation, pleural effusion)

Additional Testing Based on AEC Level

If AEC ≥1,500 cells/μL (hypereosinophilia):

• Peripheral blood smear review for morphologic abnormalities
• Serum tryptase and vitamin B12 (elevated in myeloproliferative variants)
• Flow cytometry for aberrant T-cell clones
• Molecular testing: PDGFRA, PDGFRB, FGFR1, JAK2 rearrangements (if considering primary eosinophilia) 3
• Cardiac evaluation: troponin, BNP, ECG, echocardiogram (assess for eosinophil-mediated damage) 4

Geographic-Specific Testing

If travel to Africa with freshwater exposure:

• Schistosomiasis serology is essential even if stool/urine microscopy negative (Katayama syndrome presents 2-8 weeks post-exposure with marked eosinophilia often >5 × 10⁹/L) 2

If travel to Asia:

• Consider Paragonimus serology (Swiss Tropical and Public Health Institute)
• Sputum microscopy if respiratory symptoms present 2

Management Approach

Empirical Treatment for Asymptomatic Eosinophilia

If stool microscopy negative but travel history suggestive:

Administer empirical treatment with albendazole 400 mg single dose PLUS ivermectin 200 μg/kg single dose to cover prepatent or undetected geohelminth infections (ascariasis, hookworm, strongyloidiasis) in patients >24 months 2.

CRITICAL CAVEAT: Exclude Loa loa before administering ivermectin in patients who traveled to endemic regions (Central/West Africa). Ivermectin can cause fatal encephalopathy if microfilaraemia >1,000/mL 2.

Acute Schistosomiasis (Katayama Syndrome)

If fever + urticarial rash + eosinophilia 2-8 weeks after African freshwater exposure:

• Praziquantel 25 mg/kg three times daily for 2-3 consecutive days 2
• Consider prednisolone 30 mg daily for 5 days to reduce symptom duration 2
• Repeat praziquantel at 8 weeks (eggs and immature schistosomulae are treatment-resistant; retreatment targets mature worms) 2

Loeffler's Syndrome (Larval Migration)

If fever, urticaria, wheeze, dry cough 1-2 weeks post-exposure:

• Ivermectin 200 μg/kg single dose PLUS albendazole 400 mg single dose 2
• Retreat 1 month after pulmonary symptom resolution to ensure adult worms are treated 2
• Avoid corticosteroids (risk of Strongyloides hyperinfection) 2

Strongyloidiasis

If immunocompromised or concerning for hyperinfection:

• Ivermectin 200 μg/kg on days 1,2,15, and 16 2
• Send stool AND sputum microscopy (serology may be negative in hyperinfection)
• Seek specialist advice for prolonged treatment 2

Red Flags Requiring Urgent Specialist Referral

• AEC ≥1,500 cells/μL with cardiac symptoms (troponin elevation, ECG changes)
• Evidence of end-organ damage on imaging or laboratory studies
• Suspected hyperinfection syndrome (immunocompromised with respiratory/GI symptoms)
• Neurologic symptoms (potential CNS involvement from parasites or eosinophilic infiltration)
• Failure to respond to empirical treatment within 4-6 weeks 5, 6

Follow-Up Strategy

• Recheck AEC in 4-6 weeks after empirical treatment
• Repeat stool studies if eosinophilia persists (may become positive as infection matures)
• Reassess for end-organ damage if hypereosinophilia continues
• If eosinophilia persists without identified cause after comprehensive workup, consider referral to hematology for evaluation of primary eosinophilic disorders (lymphocytic variant HES, idiopathic HES, or myeloproliferative variants) 6, 3

Common Pitfalls

1. Treating with ivermectin without excluding Loa loa in patients from endemic regions—can be fatal 2
2. Using corticosteroids empirically before excluding Strongyloides—risk of hyperinfection 2
3. Single-dose praziquantel for schistosomiasis—immature forms are resistant; 8-week retreatment is essential 2
4. Attributing hypereosinophilia to allergy alone—this is rarely if ever the sole cause at AEC ≥1,500 cells/μL 1
5. Ignoring cardiac evaluation in hypereosinophilia—eosinophil-mediated myocarditis can be life-threatening 4